Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Malte Peters
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 137
- Beta
- 1.22
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 40.87
Financials
Revenue
$0.00-100.0%Net Income
$-68.39MEBITDA
$-67.97MFree Cash Flow
$-37.22MEPS (diluted)
$-0.39Shares Outstanding (diluted)
173.93M+98.8%Operating Expenses
$78.12MCash & Debt
$977.50MRevenue by Segment (annual)
$62.38MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $62.38M | $-101.59M | $-0.87 |
| 2024 | $42.07M | $-130.30M | $-1.19 |
| 2023 | $36.53M | $-101.74M | $-1.08 |
| 2022 | $24.86M | $-108.18M | $-1.23 |
| 2021 | $37.04M | $-58.23M | $-0.94 |
| 2020 | $7.66M | $-51.97M | $-1.62 |
| 2019 | $24.65M | $-14.10M | $-1.57 |
Valuation
TNGXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+60.00%Social Signal Score
Mentions (12)
- Newsglobenewswire.com·13d ago·Positive
… to be disclosed in January 2027 Cash position of $977.5 million as of September 30, 2026 BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today reported financial results for the third quarter ended September 30, 2026, and provided business highlights. “In 2026, Tango has made significant strides towards bringi…
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at Guggenheim's 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 8:00 AM EST.
View source ↗ - Newsseekingalpha.com·25d ago·Neutral
…an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer, outperforming historical controls. I view the ESMO-driven sell-off as overdone, given TNGX's strong cash position ($1B), FDA-aligned registrational design, and underappreciated dual-primary endpoint trial. Vopimetostat enables daraxonrasib dose-sparing, reducing toxicity and cost, making TNGX a preferred RAS combination partner with expanding partnership optionality.
View source ↗ - Newszacks.com·27d ago·Neutral
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
View source ↗ - Newsseekingalpha.com·30d ago·Positive
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
View source ↗ - Newsmarketbeat.com·30d ago·Neutral
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate Tango Therapeutics NASDAQ: TNGX said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma, or PDAC.
View source ↗ - Newsbenzinga.com·30d ago·Negative
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers.
View source ↗ - Newsinvestors.com·30d ago·Negative
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy 82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib
View source ↗ - Newszacks.com·73d ago·Neutral
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsseekingalpha.com·98d ago·Positive
…d the opportunity, although its final design, timing, and regulatory path remain unsettled. Additional combination, lung-cancer, and CNS readouts should show whether TNGX is building a broader PRMT5 franchise or relying too heavily on one early dataset.
View source ↗ - Newszacks.com·102d ago·Negative
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.42 per share
Typical surprise -1.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.39 vs $-0.35miss
- Mon, Aug 10$-0.37 vs $-0.32miss
- Wed, May 13$-0.32 vs $-0.31miss
- Thu, Mar 5$-0.29 vs $-0.31beat
- Tue, Nov 4$0.13 vs $0.01beat
- Tue, Aug 5$-0.35 vs $-0.35beat
Estimates and results for TNGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TNGX officers and directors.
- Bought
- —
- Sold
- $34.5m
0 trades
38 trades
- Ketchum John Bsold
- Crystal Adamsold
- Crystal Adamsold
- Crystal Adamsold
- Newcomb Jessicasold
- Newcomb Jessicasold
- Crystal Adamsold
- Crystal Adamsold
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TNGX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
